1
|
Yamashita T, Ahmad S, Wright KN, Roberts DJ, VonCannon JL, Wang H, Groban L, Dell'Italia LJ, Ferrario CM. Noncanonical Mechanisms for Direct Bone Marrow Generating Ang II (Angiotensin II) Predominate in CD68 Positive Myeloid Lineage Cells. Hypertension 2019; 75:500-509. [PMID: 31813348 DOI: 10.1161/hypertensionaha.119.13754] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Bone marrow (BM) Ang II (angiotensin II) is a major participant in the regulation of hematopoiesis and immunity. The novel tissue substrate Ang-(1-12) [angiotensin-(1-12)] and its cleaving enzyme chymase are an essential source of Ang II production in cardiac tissue. We hypothesized this noncanonical chymase-mediated Ang II-producing mechanism exists in the BM tissue. Immunohistostaining and flow cytometry confirmed the presence of Ang-(1-12) immunoreaction in the BM of SD (Sprague Dawley) rats. Chymase-mediated Ang II-producing activity in BM was ≈1000-fold higher than ACE (angiotensin-converting enzyme)-mediated Ang II-producing activity (4531±137 and 4.2±0.3 fmol/min per mg, respectively; n=6; P<0.001) and 280-fold higher than chymase activity in the left ventricle of 16.3±1.7 fmol/min per mg (P<0.001). Adding a selective chymase inhibitor, TEI-F00806, eliminated almost all 125I-Ang II production. Flow cytometry demonstrated that delta median fluorescence intensity of chymase in cluster of differentiation 68 positive cells was significantly higher than that in cluster of differentiation 68 negative cells (1546±157 and 222±48 arbitrary units, respectively; P=0.0021). Cluster of differentiation 68 positive and side scatter low subsets, considered to be myeloid progenitors, express the highest chymase fluorescence intensity in rat BM. Chymase activity and cellular expression was similar in both male and female rats. In conclusion, myeloid lineage cells, especially myeloid progenitors, have an extraordinary Ang II-producing activity by chymase in the BM.
Collapse
Affiliation(s)
- Tomohisa Yamashita
- From the Department of Surgery (T.Y., S.A., K.N.W., D.J.R., J.L.V., C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Sarfaraz Ahmad
- From the Department of Surgery (T.Y., S.A., K.N.W., D.J.R., J.L.V., C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Kendra N Wright
- From the Department of Surgery (T.Y., S.A., K.N.W., D.J.R., J.L.V., C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Drew J Roberts
- From the Department of Surgery (T.Y., S.A., K.N.W., D.J.R., J.L.V., C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Jessica L VonCannon
- From the Department of Surgery (T.Y., S.A., K.N.W., D.J.R., J.L.V., C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Hao Wang
- Department of Anesthesiology (H.W., L.G.), Wake Forest School of Medicine, Winston-Salem, NC.,Department of Internal Medicine-Molecular Medicine; (H.W., L.G.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Leanne Groban
- Department of Anesthesiology (H.W., L.G.), Wake Forest School of Medicine, Winston-Salem, NC.,Department of Internal Medicine-Molecular Medicine; (H.W., L.G.), Wake Forest School of Medicine, Winston-Salem, NC
| | - Louis J Dell'Italia
- Department of Medicine, Division of Cardiovascular Disease, University of Alabama at Birmingham (L.J.D.)
| | - Carlos M Ferrario
- From the Department of Surgery (T.Y., S.A., K.N.W., D.J.R., J.L.V., C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC.,Department of Physiology-Pharmacology (C.M.F.), Wake Forest School of Medicine, Winston-Salem, NC
| |
Collapse
|
2
|
CARNEIRO GIANED, SIELSKI MICHELIS, VIEIRA CRISTIANOPEDROSO, COSTA FABIOTRINDADEMARANHÃO, WERNECK CLAUDIOC, VICENTE CRISTINAP. Administration of endothelial progenitor cells accelerates the resolution of arterial thrombus in mice. Cytotherapy 2019; 21:444-459. [DOI: 10.1016/j.jcyt.2019.01.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 12/11/2018] [Accepted: 01/01/2019] [Indexed: 12/31/2022]
|
3
|
Shi X, Zhang W, Yin L, Chilian WM, Krieger J, Zhang P. Vascular precursor cells in tissue injury repair. Transl Res 2017; 184:77-100. [PMID: 28284670 PMCID: PMC5429880 DOI: 10.1016/j.trsl.2017.02.002] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Revised: 12/25/2016] [Accepted: 02/14/2017] [Indexed: 12/22/2022]
Abstract
Vascular precursor cells include stem cells and progenitor cells giving rise to all mature cell types in the wall of blood vessels. When tissue injury occurs, local hypoxia and inflammation result in the generation of vasculogenic mediators which orchestrate migration of vascular precursor cells from their niche environment to the site of tissue injury. The intricate crosstalk among signaling pathways coordinates vascular precursor cell proliferation and differentiation during neovascularization. Establishment of normal blood perfusion plays an essential role in the effective repair of the injured tissue. In recent years, studies on molecular mechanisms underlying the regulation of vascular precursor cell function have achieved substantial progress, which promotes exploration of vascular precursor cell-based approaches to treat chronic wounds and ischemic diseases in vital organ systems. Verification of safety and establishment of specific guidelines for the clinical application of vascular precursor cell-based therapy remain major challenges in the field.
Collapse
Affiliation(s)
- Xin Shi
- Department of Integrative Medical Sciences, College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio
| | - Weihong Zhang
- Department of Basic Medicine, School of Nursing, Zhengzhou University, Zhengzhou, Henan Province, PR China
| | - Liya Yin
- Department of Integrative Medical Sciences, College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio
| | - William M Chilian
- Department of Integrative Medical Sciences, College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio
| | - Jessica Krieger
- Department of Integrative Medical Sciences, College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio
| | - Ping Zhang
- Department of Integrative Medical Sciences, College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio.
| |
Collapse
|
4
|
Extracellular Vesicles Derived from Adipose Mesenchymal Stem Cells Regulate the Phenotype of Smooth Muscle Cells to Limit Intimal Hyperplasia. Cardiovasc Drugs Ther 2017; 30:111-8. [PMID: 26650931 DOI: 10.1007/s10557-015-6630-5] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
PURPOSE Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) play important roles in the reduction of inflammation in multiple disease models. However, their role in vein graft (VG) remodeling is undefined. We aimed to investigate the effect of EVs from adipose MSCs (ADMSC-EVs) on VG intimal hyperplasia and to explore the possible mechanisms. METHODS After generation and characterization of control-EVs and ADMSC-EVs in vitro, we investigated their effect on the proliferation and migration of vascular smooth muscle cells (VSMCs) in vitro. Next, we established a mouse model of VG transplantation. Mice underwent surgery and received control-EVs or ADMSC-EVs by intraperitoneal injection every other day for 20 days. VG remodeling was evaluated after 4 weeks. We also assessed the effect of ADMSC-EVs on macrophage migration and inflammatory cytokine expression. RESULTS Significant inhibitory effects of ADMSC-EVs on in vitro VSMC proliferation (p < 0.05) and migration (p < 0.05) were observed compared with control-EVs. The extent of intimal hyperplasia was significantly decreased in ADMSC-EV-treated mice compared with control-EV-treated mice (26 ± 8.4 vs. 45 ± 9.0 μm, p < 0.05). A reduced presence of macrophages was observed in ADMSC-EV-treated mice (p < 0.05). Significantly decreased expression of inflammatory cytokines interleukin (IL)-6 and monocyte chemoattractant protein-1 (MCP-1) was also found in the ADMSC-EV-treated group (both p < 0.05). In addition, phosphorylation of Akt, Erk1/2, and p38 in VGs was decreased in the ADMSC-EV-treated group. CONCLUSIONS We demonstrated that ADMSC-EVs exert an inhibitory effect on VG neointima formation by regulating VSMC proliferation and migration, macrophage migration, inflammatory cytokine expression, and the related signaling pathways.
Collapse
|
5
|
Kyuragi R, Matsumoto T, Harada Y, Saito S, Onimaru M, Nakatsu Y, Tsuzuki T, Nomura M, Yonemitsu Y, Maehara Y. BubR1 Insufficiency Inhibits Neointimal Hyperplasia Through Impaired Vascular Smooth Muscle Cell Proliferation in Mice. Arterioscler Thromb Vasc Biol 2015; 35:341-7. [DOI: 10.1161/atvbaha.114.304737] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Objective—
BubR1, a cell cycle–related protein, is an essential component of the spindle checkpoint that regulates cell division. Mice with BubR1 expression reduced to 10% of the normal level display a phenotype characterized by progeria; however, the involvement of BubR1 in vascular diseases is still unknown. We generated mice in which BubR1 expression was reduced to 20% (
BubR1
L/L
mice) of that in wild-type mice (
BubR1
+/+
) to investigate the effects of BubR1 on arterial intimal hyperplasia.
Approach and Results—
Ten-week-old male
BubR1
L/L
and age-matched wild-type littermates (
BubR1
+/+
) were used in this study. The left common carotid artery was ligated, and histopathologic examinations were conducted 4 weeks later. Bone marrow transplantation was also performed. Vascular smooth muscle cells (VSMCs) were isolated from the thoracic aorta to examine cell proliferation, migration, and cell cycle progression. Severe neointimal hyperplasia was observed after artery ligation in
BubR1
+/+
mice, whereas
BubR1
L/L
mice displayed nearly complete inhibition of neointimal hyperplasia. Bone marrow transplantation from all donors did not affect the reconstitution of 3 hematopoietic lineages, and neointimal hyperplasia was still suppressed after bone marrow transplantation from
BubR1
+/+
mice to
BubR1
L/L
mice. VSMC proliferation was impaired in
BubR1
L/L
mice because of delayed entry into the S phase. VSMC migration was unaffected in these
BubR1
L/L
mice. p38 mitogen–activated protein kinase–inhibited VSMCs showed low expression of BubR1, and BubR1-inhibited VSMCs showed low expression of p38.
Conclusions—
BubR1 may represent a new target molecule for treating pathological states of vascular remodeling, such as restenosis after angioplasty.
Collapse
Affiliation(s)
- Ryoichi Kyuragi
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Takuya Matsumoto
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Yui Harada
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Satoru Saito
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Mitsuho Onimaru
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Yoshimichi Nakatsu
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Teruhisa Tsuzuki
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Masatoshi Nomura
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Yoshikazu Yonemitsu
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| | - Yoshihiko Maehara
- From the Department of Surgery and Science, Graduate School of Medical Sciences (R.K., T.M., Y.M.), R&D Laboratory for Innovative Biotherapeutics, Graduate School of Pharmaceutical Sciences (Y.H., S.S., Y.Y.), Department of Pathology, Graduate School of Medical Sciences (M.O.), Department of Medical Biophysics and Radiation Biology, Graduate School of Medical Sciences (Y.N., T.T.), and Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences (M.N.), Kyushu University
| |
Collapse
|
6
|
Brenner C, Kränkel N, Kühlenthal S, Israel L, Remm F, Fischer C, Herbach N, Speer T, Grabmaier U, Laskowski A, Gross L, Theiss H, Wanke R, Landmesser U, Franz WM. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells. Int J Cardiol 2014; 177:266-75. [PMID: 25499391 DOI: 10.1016/j.ijcard.2014.09.016] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/18/2014] [Revised: 08/06/2014] [Accepted: 09/15/2014] [Indexed: 01/12/2023]
Abstract
BACKGROUND Endothelial injuries regularly occur in atherosclerosis and during interventional therapies of the arterial occlusive disease. Disturbances in the endothelial integrity can lead to insufficient blood supply and bear the risk of thrombus formation and acute vascular occlusion. At present, effective therapeutics to restore endothelial integrity are barely available. We analyzed the effect of pharmacological DPP-4-inhibition by Sitagliptin on endogenous progenitor cell-based endothelial regeneration via the SDF-1α/CXCR4-axis after acute endothelial damage in a mouse model of carotid injury. METHODS AND RESULTS Induction of a defined endothelial injury was performed in the carotid artery of C57Bl/6 mice which led to a local upregulation of SDF-1α expression. Animals were treated with placebo, Sitagliptin or Sitagliptin+AMD3100. Using mass spectrometry we could prove that Sitagliptin prevented cleavage of the chemokine SDF-1α. Accordingly, increased SDF-1α concentrations enhanced recruitment of systemically applied and endogenous circulating CXCR4+ progenitor cells to the site of vascular injury followed by a significantly accelerated reendothelialization as compared to placebo-treated animals. Improved endothelial recovery, as well as recruitment of circulating CXCR4+ progenitor cells (CD133+, Flk1+), was reversed by CXCR4-antagonization through AMD3100. In addition, short-term Sitagliptin treatment did not significantly promote neointimal or medial hyperplasia. CONCLUSION Sitagliptin can accelerate endothelial regeneration after acute endothelial injury. DPP-4 inhibitors prevent degradation of the chemokine SDF-1α and thus improve the recruitment of regenerative circulating CXCR4+ progenitor cells which mediate local endothelial cell proliferation without adversely affecting vessel wall architecture.
Collapse
Affiliation(s)
- Christoph Brenner
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany; Institute of Physiology, Cardiovascular Research, University of Zurich, Campus Irchel, Zurich, Switzerland; Department of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.
| | - Nicolle Kränkel
- Department of Cardiology, University Hospital Zurich, Zurich, Switzerland; Institute of Physiology, Cardiovascular Research, University of Zurich, Campus Irchel, Zurich, Switzerland
| | - Sarah Kühlenthal
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Lars Israel
- Institute of Molecular Biology, Adolf-Butenandt-Institute, Ludwig-Maximilians-University, Munich, Germany
| | - Friederike Remm
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Cornelia Fischer
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Nadja Herbach
- Institute of Veterinary Pathology, Ludwig-Maximilians-University, Munich, Germany
| | - Timo Speer
- Institute of Physiology, Cardiovascular Research, University of Zurich, Campus Irchel, Zurich, Switzerland; Department of Internal Medicine IV, Saarland University Hospital, Homburg/Saar, Germany
| | - Ulrich Grabmaier
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Alexandra Laskowski
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Lisa Gross
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Hans Theiss
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany
| | - Rüdiger Wanke
- Institute of Veterinary Pathology, Ludwig-Maximilians-University, Munich, Germany
| | - Ulf Landmesser
- Department of Cardiology, University Hospital Zurich, Zurich, Switzerland; Institute of Physiology, Cardiovascular Research, University of Zurich, Campus Irchel, Zurich, Switzerland
| | - Wolfgang-Michael Franz
- Department of Internal Medicine I, Ludwig-Maximilians-University, Campus Grosshadern, Munich, Germany; Department of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.
| |
Collapse
|
7
|
A novel molecule Me6TREN promotes angiogenesis via enhancing endothelial progenitor cell mobilization and recruitment. Sci Rep 2014; 4:6222. [PMID: 25164363 PMCID: PMC5385830 DOI: 10.1038/srep06222] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2014] [Accepted: 08/11/2014] [Indexed: 12/29/2022] Open
Abstract
Critical limb ischaemia is the most severe clinical manifestation of peripheral arterial disease. The circulating endothelial progenitor cells (EPCs) play important roles in angiogenesis and ischemic tissue repair. The increase of circulating EPC numbers by using mobilization agents is critical for obtaining a better therapeutic outcome in patients with ischemic disease. Here, we firstly report a novel small molecule, Me6TREN (Me6), can efficiently mobilize EPCs into the blood circulation. Single injection of Me6 induced a long-lasting increase in circulating Flk-1+ Sca-1+ EPC numbers. In a mouse hind limb ischemia (HLI) model, local intramuscular transplantation of these Me6-mobilized cells accelerated the blood flow restoration in the ischemic muscles. More importantly, systemic administration of Me6 notably increased the capillary density, arteriole density and regenerative muscle weight in the ischemic tissue of HLI. Mechanistically, we found Me6 reduced stromal cell-derived factor-1α level in bone marrow by up-regulation of matrix metallopeptidase-9 expression, which allowed the dissemination of EPCs into peripheral blood. These data indicate that Me6 may represent a potentially useful therapy for ischemic disease via enhancing autologous EPC recruitment and promote angiogenesis.
Collapse
|
8
|
Chatterjee M, Gawaz M. Platelet-derived CXCL12 (SDF-1α): basic mechanisms and clinical implications. J Thromb Haemost 2013; 11:1954-67. [PMID: 24024928 DOI: 10.1111/jth.12404] [Citation(s) in RCA: 74] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Indexed: 12/19/2022]
Abstract
Platelets are a major source of CXCL12 (stromal cell-derived factor -1α, SDF-1α) and store CXCL12 as part of their α-granule secretome. Platelet activation enhances surface expression and release of CXCL12. Platelets and megakaryocytes express CXCR4, the major receptor for CXCL12, and interaction of CXCL12 with CXCR4 regulates megakaryopoiesis and the function of circulating platelets. Platelet-derived CXCL12 also modulates paracrine mechanisms such as chemotaxis, adhesion, proliferation and differentiation of nucleated cells, including progenitor cells. Platelet-derived CXCL12 enhances peripheral recruitment of progenitor cells to the sites of vascular and tissue injury both in vitro and in vivo and thereby promotes repair mechanisms. CXCL12 expression on platelets is elevated in patients with acute myocardial infarction, correlates with the number of circulating progenitor cells, is associated with preservation of myocardial function and is an independent predictor of clinical outcome. Administration of recombinant CXCL12 reduces infarct size following transient ischemia in mice. The present review summarizes the role of platelet-derived CXCL12 in cardiovascular biology and its diagnostic and therapeutic implications.
Collapse
Affiliation(s)
- M Chatterjee
- Medizinische Klinik III, Kardiologie und Kreislauferkrankungen, Eberhard Karls Universität, Tübingen, Germany
| | | |
Collapse
|
9
|
Chen J, Chen J, Chen S, Zhang C, Zhang L, Xiao X, Das A, Zhao Y, Yuan B, Morris M, Zhao B, Chen Y. Transfusion of CXCR4-primed endothelial progenitor cells reduces cerebral ischemic damage and promotes repair in db/db diabetic mice. PLoS One 2012. [PMID: 23185548 PMCID: PMC3503762 DOI: 10.1371/journal.pone.0050105] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
This study investigated the role of stromal cell-derived factor-1α (SDF-1α)/CXC chemokine receptor 4 (CXCR4) axis in brain and endothelial progenitor cells (EPCs), and explored the efficacy of CXCR4 primed EPCs in treating ischemic stroke in diabetes. The db/db diabetic and db/+ mice were used in this study. Levels of plasma SDF-1α and circulating CD34+CXCR4+ cells were measured. Brain SDF-1α and CXCR4 expression were quantified at basal and after middle cerebral artery occlusion (MCAO). In in vitro study, EPCs were transfected with adenovirus carrying null (Ad-null) or CXCR4 (Ad-CXCR4) followed with high glucose (HG) treatment for 4 days. For pathway block experiments, cells were pre-incubated with PI3K inhibitor or nitric oxide synthase (NOS) inhibitor for two hours. The CXCR4 expression, function and apoptosis of EPCs were determined. The p-Akt/Akt and p-eNOS/eNOS expression in EPCs were also measured. In in vivo study, EPCs transfected with Ad-null or Ad-CXCR4 were infused into mice via tail vein. On day 2 and 7, the cerebral blood flow, neurologic deficit score, infarct volume, cerebral microvascular density, angiogenesis and neurogenesis were determined. We found: 1) The levels of plasma SDF-1α and circulating CD34+CXCR4+ cells were decreased in db/db mice; 2) The basal level of SDF-1α and MCAO-induced up-regulation of SDF-1α/CXCR4 axis were reduced in the brain of db/db mice; 3) Ad-CXCR4 transfection increased CXCR4 expression in EPCs and enhanced EPC colonic forming capacity; 4) Ad-CXCR4 transfection prevented EPCs from HG-induced dysfunction (migration and tube formation) and apoptosis via activation of PI3K/Akt/eNOS signal pathway; 4) Ad-CXCR4 transfection enhanced the efficacy of EPC infusion in attenuating infarct volume and promoting angiogenesis and neurogenesis. Our data suggest that Ad-CXCR4 primed EPCs have better therapeutic effects for ischemia stroke in diabetes than unmodified EPCs do.
Collapse
Affiliation(s)
- Ji Chen
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
- Clinical Research Center and Department of Neurology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People’s Republic of China
| | - Jianying Chen
- Clinical Research Center and Department of Neurology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People’s Republic of China
| | - Shuzhen Chen
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
| | - Cheng Zhang
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
| | - Liangqing Zhang
- Clinical Research Center and Department of Neurology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People’s Republic of China
| | - Xiang Xiao
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
| | - Avik Das
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
| | - Yuhui Zhao
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
- Department of Neurology, the First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, People’s Republic of China
| | - Bin Yuan
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
- Clinical Research Center and Department of Neurology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People’s Republic of China
| | - Mariana Morris
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
| | - Bin Zhao
- Clinical Research Center and Department of Neurology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People’s Republic of China
| | - Yanfang Chen
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, United States of America
- Clinical Research Center and Department of Neurology, the Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong, People’s Republic of China
- * E-mail:
| |
Collapse
|
10
|
Abstract
Modulation of the RAS (renin–angiotensin system), in particular of the function of the hormones AngII (angiotensin II) and Ang-(1–7) [angiotensin-(1–7)], is an important target for pharmacotherapy in the cardiovascular system. In the classical view, such modulation affects cardiovascular cells to decrease hypertrophy, fibrosis and endothelial dysfunction, and improves diuresis. In this view, excessive stimulation of AT1 receptors (AngII type 1 receptors) fulfils a detrimental role, as it promotes cardiovascular pathogenesis, and this is opposed by stimulation of the AT2 receptor (angiotensin II type 2 receptor) and the Ang-(1–7) receptor encoded by the Mas proto-oncogene. In recent years, this view has been broadened with the observation that the RAS regulates bone marrow stromal cells and stem cells, thus involving haematopoiesis and tissue regeneration by progenitor cells. This change of paradigm has enlarged the field of perspectives for therapeutic application of existing as well as newly developed medicines that alter angiotensin signalling, which now stretches beyond cardiovascular therapy. In the present article, we review the role of AngII and Ang-(1–7) and their respective receptors in haematopoietic and mesenchymal stem cells, and discuss possible pharmacotherapeutical implications.
Collapse
|
11
|
Daniel JM, Dutzmann J, Bielenberg W, Widmer-Teske R, Gündüz D, Hamm CW, Sedding DG. Inhibition of STAT3 signaling prevents vascular smooth muscle cell proliferation and neointima formation. Basic Res Cardiol 2012; 107:261. [PMID: 22418922 PMCID: PMC3350628 DOI: 10.1007/s00395-012-0261-9] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Revised: 02/22/2012] [Accepted: 03/07/2012] [Indexed: 12/11/2022]
Abstract
Dedifferentiation, migration, and proliferation of resident vascular smooth muscle cells (SMCs) are key components of neointima formation after vascular injury. Activation of signal transducer and activator of transcription-3 (STAT3) is suggested to be critically involved in this process, but the complex regulation of STAT3-dependent genes and the functional significance of inhibiting this pathway during the development of vascular proliferative diseases remain elusive. In this study, we demonstrate that STAT3 was activated in neointimal lesions following wire-induced injury in mice. Phosphorylation of STAT3 induced trans-activation of cyclin D1 and survivin in SMCs in vitro and in neointimal cells in vivo, thus promoting proliferation and migration of SMCs as well as reducing apoptotic cell death. WP1066, a highly potent inhibitor of STAT3 signaling, abrogated phosphorylation of STAT3 and dose-dependently inhibited the functional effects of activated STAT3 in stimulated SMCs. The local application of WP1066 via a thermosensitive pluronic F-127 gel around the dilated arteries significantly inhibited proliferation of neointimal cells and decreased the neointimal lesion size at 3 weeks after injury. Even though WP1066 application attenuated the injury-induced up-regulation of the chemokine RANTES at 6 h after injury, there was no significant effect on the accumulation of circulating cells at 1 week after injury. In conclusion, these data identify STAT3 as a key molecule for the proliferative response of SMC and neointima formation. Moreover, inhibition of STAT3 by the potent and specific compound WP1066 might represent a novel and attractive approach for the local treatment of vascular proliferative diseases.
Collapse
Affiliation(s)
- Jan-Marcus Daniel
- Department of Cardiology, Justus-Liebig-University, Giessen, Germany
| | | | | | | | | | | | | |
Collapse
|
12
|
Hamesch K, Subramanian P, Li X, Dembowsky K, Chevalier E, Weber C, Schober A. The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation. Thromb Haemost 2012; 107:356-68. [PMID: 22234341 DOI: 10.1160/th11-07-0453] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2011] [Accepted: 11/29/2011] [Indexed: 11/05/2022]
Abstract
Impaired endothelial recovery after the implantation of drug-eluting stents is a major concern because of the increased risk for late stent thrombosis. The disruption of the chemokine axis CXCL12/CXCR4 inhibits neointima formation by blocking the recruitment of smooth muscle progenitor cells. To directly compare a CXCR4-targeting treatment strategy with drugs that are currently used for stent coating, we studied the effects of the CXCR4 antagonist POL5551 and the drug sirolimus on neointima formation. Apolipoprotein E-deficient mice were treated with POL5551 or sirolimus continuously for 28 days after a carotid wire injury. POL5551 inhibited neointima formation by 63% (for a dosage of 2 mg/kg/day) and by 70% (for a dosage of 20 mg/kg/day). In comparison, sirolimus reduced the neointimal area by 69%. In contrast to treatment with POL5551 during the first three days after injury, injection of POL5551 (20 mg/kg) once per day for 28 days diminished neointimal hyperplasia by 53%. An analysis of the cellular composition of the neointima showed a reduction in the relative smooth muscle cell (SMC) and macrophage content in mice that had been treated with a high dose of POL5551. In contrast, the diminished SMC content after sirolimus treatment was associated with a neointimal enrichment of macrophages. Furthermore, endothelial recovery was impaired by sirolimus, but not by POL5551. Therefore, the inhibition of CXCR4 by POL5551 is equally effective in preventing neointima formation as sirolimus, but POL5551 might be more beneficial because treatment with it results in a more stable lesion phenotype and because it does not impair re-endothelialisation.
Collapse
Affiliation(s)
- Karim Hamesch
- Institute for Molecular Cardiovascular Research, RWTH Aachen University, Aachen, Germany
| | | | | | | | | | | | | |
Collapse
|
13
|
Ikesue M, Matsui Y, Ohta D, Danzaki K, Ito K, Kanayama M, Kurotaki D, Morimoto J, Kojima T, Tsutsui H, Uede T. Syndecan-4 Deficiency Limits Neointimal Formation After Vascular Injury by Regulating Vascular Smooth Muscle Cell Proliferation and Vascular Progenitor Cell Mobilization. Arterioscler Thromb Vasc Biol 2011; 31:1066-74. [DOI: 10.1161/atvbaha.110.217703] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Syndecan-4 (Syn4) is a heparan sulfate proteoglycan and works as a coreceptor for various growth factors. We examined whether Syn4 could be involved in the development of neointimal formation in vivo.
Methods and Results—
Wild-type (WT) and Syn4-deficient (Syn4
−/−
) mice were subjected to wire-induced femoral artery injury.
Syn4
mRNA was upregulated after vascular injury in WT mice. Neointimal formation was attenuated in Syn4
−/−
mice, concomitantly with the reduction of Ki67-positive vascular smooth muscle cells (VSMCs). Basic-fibroblast growth factor– or platelet-derived growth factor-BB–induced proliferation, extracellular signal-regulated kinase activation, and expression of cyclin D1 and Bcl-2 were impaired in VSMCs from Syn4
−/−
mice. To examine the role of Syn4 in bone marrow (BM)–derived vascular progenitor cells (VPCs) and vascular walls, we generated chimeric mice by replacing the BM cells of WT and Syn4
−/−
mice with those of WT or Syn4
−/−
mice. Syn4 expressed by both vascular walls and VPCs contributed to the neointimal formation after vascular injury. Although the numbers of VPCs were compatible between WT and Syn4
−/−
mice, mobilization of VPCs from BM after vascular injury was defective in Syn4
−/−
mice.
Conclusion—
Syn4 deficiency limits neointimal formation after vascular injury by regulating VSMC proliferation and VPC mobilization. Therefore, Syn4 may be a novel therapeutic target for preventing arterial restenosis after angioplasty.
Collapse
Affiliation(s)
- Masahiro Ikesue
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Yutaka Matsui
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Daichi Ohta
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Keiko Danzaki
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Koyu Ito
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Masashi Kanayama
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Daisuke Kurotaki
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Junko Morimoto
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Tetsuhito Kojima
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Hiroyuki Tsutsui
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| | - Toshimitsu Uede
- From the Division of Molecular Immunology (M.I., D.O., K.D., K.I., M.K., J.M., T.U.) and Department of Matrix Medicine (Y.M., D.K., T.U.), Institute for Genetic Medicine, Hokkaido University, Sapporo, Japan; Department of Medical Technology, Nagoya University School of Health Sciences, Nagoya, Japan (T.K.); Department of Cardiovascular Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan (H.T.)
| |
Collapse
|